Track topics on Twitter Track topics that are important to you
The European Commission has followed the EMA’s CHMP positive opinion by approving Novartis’ Zykadia for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours are ALK-positive.
Original Article: Novartis gains first-line approval for Zykadia in lung cancerNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...